摘要
本文综述了强迫症多巴胺能作用的动物模型、遗传多态性、脑神经影像学和神经生化、神经药理等方面的证据。
出处
《国际精神病学杂志》
2006年第2期116-119,共4页
Journal Of International Psychiatry
参考文献14
-
1Blier P, de Montigny C. Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses. Biol Psychiatry, 1998; 44(5): 313-323.
-
2Campbell KM, McGrath MJ, Burton FH. Differential response of cortical-limbic neuropotentiated compulsive mice to dopamine D1 and D2 receptor antagonists. Eur J Pharmacol. 1999; 371(2-3): 103-111.
-
3Sullivan RM, Eckert M J, Tse WS, et al. Effects of quinpirole on central dopamine systems in sensitized and non-sensitized rats. Neuroscience, 1998; 83(3):781-789.
-
4Joel D, Doljansky J. Selective alleviation of compulsive leverpressing in rats by D(1), but not D(2), blockade: possible implications for the involvement of D(1) receptors in obsessivecompulsive disorder. Neuropsychopharmacology, 2003;28(1) : 77-85.
-
5Little KY, Zhang L, Desmond T, et al. Striatal dopaminergic abnormalities in human cocaine users. Am J Psychiatry, 1999;156(2) : 238-245.
-
6Metion O, Yazici K, Tot S, et al. Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder, J Clin Psychopharmacol. 2003; 18(4): 463-467.
-
7喻东山.强迫症治疗的新进展[J].中华精神科杂志,2005,38(1):50-52. 被引量:65
-
8Ramasubbu R, Antiobsessional effect of risperidone add-on treatment in serotonin reuptake inhibitor-refractory obsessivecompulsive disorder may be dose-dependent. Arch Gen Psychiatry, 2002; 59(4): 472-473.
-
9Van der Wee N, Stevens H, Harderman H, et al. Enhanced densities of dopamine but not of serotonin transporters in psychotropic-naive patients with obsessive-compulsive disorder. J Nucl Med. 2001; 42(2): 238.
-
10Kim CH, Koo MS, Cheon KA, et al. Dopamine transporter density of basal ganglia assessed with [(123)I] IPT SPECT in obsessive-compulsive disorder. Eur J Nucl Med Mol Imaging,2003; 30(12) : 1637-1643.
二级参考文献14
-
1Saxena S, Rauch SL. Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder. Psychiatr Clin North Am, 2000, 23:563-586.
-
2Richelson E. Preclinical pharmacology of neuroleptics: focus on new generation compounds. J Clin Psychiatry, 1996, 57 Suppl 11:4-11.
-
3Gabriels L, Cosyns P, Nuttin B, et al. Deep brain stimulation for treatment-refractory obsessive-compulsive disorder: psychopa-thological and neuropsychological outcome in three cases. Acta Psychiatr Scand, 2003, 107:275-282.
-
4Flament MF, Bisserbe JC. Pharmacologic treatment of obsessive-compulsive disorder: comparative studies. J Clin Psychiatry, 1997, 58 Suppl 12:18-22.
-
5Hollander E, Kaplan A, Allen A, et al. Pharmacotherapy for obsessive-compulsive disorder. Psychiatr Clin North Am, 2000, 23:643-656.
-
6Gorman JM, Kent JM. SSRIs and SNRIs: broad spectrum of efficacy beyond major depression. J Clin Psychiatry, 1999, 60 Suppl 4:33-38.
-
7Hollander E, Bienstock CA, Koran LM, et al. Refractory obsessive-compulsive disorder: state-of-the-art treatment. J Clin Psychiatry, 2002, 63 Suppl 6:20-29.
-
8McDougle CJ. Update on pharmacologic management of OCD: agents and augmentation. J Clin Psychiatry, 1997, 58 Suppl 12:11-17.
-
9Pigott TA. Gender differences in the epidemiology and treatment of anxiety disorders. J Clin Psychiatry, 1999, 60 Suppl 18:4-15.
-
10Stein DJ. Advances in the neurobiology of obsessive-compulsive disorder:implications for conceptualizing putative obsessive-compulsive and spectrum disorders. Psychiatr Clin North Am, 2000, 23:545-562.
共引文献64
-
1苗永成,杨凤池.强迫症1例临床报道[J].医学信息,2017,30(10):188-189.
-
2苏中华,成义仁.强迫症治疗的定性评估和难治性强迫症的治疗策略[J].山东精神医学,2005,18(3):201-203.
-
3周小东,丁永涛,李秀珍,刘知源.阿立哌唑与氯米帕明治疗强迫症的疗效对照分析[J].四川精神卫生,2006,19(3):147-149. 被引量:2
-
4王玉,刘盈,汤艳清.阿立哌唑作为增效剂治疗难治性强迫症的临床观察[J].中国行为医学科学,2006,15(9):800-801. 被引量:9
-
5周小东,丁永涛,李秀珍,刘知源.阿立哌唑与氯米帕明治疗强迫症的临床对照研究[J].华北国防医药,2006,18(4):241-243.
-
6王海滨,肖一妙,牛犇,段存信.无抽搐电休克与氯丙咪嗪联合治疗强迫症的对照研究[J].中国健康心理学杂志,2006,14(5):566-568. 被引量:1
-
7范红霞,申荷永,张敏.近20年国内外强迫症心理治疗研究进展及动态[J].中国健康心理学杂志,2006,14(6):692-695. 被引量:12
-
8张勇,李恒芬,杨世昌,邹韶红,云珍,贾福军.中学生强迫症的认知倾向、D型人格与家庭环境的关系[J].实用儿科临床杂志,2006,21(24):1713-1714. 被引量:8
-
9王玉伟,曹丽华,杨丽芹,王玉翠,王泽鉴,盖万良.利培酮合并氯丙咪嗪治疗强迫症临床分析[J].中国民康医学,2007,19(5):178-180.
-
10汪春运.有抽动史的精神分裂症强迫症状用帕罗西汀联合利培酮治疗有效1例[J].神经疾病与精神卫生,2007,7(4):328-328.
同被引文献29
-
1周云飞,张亚林.难治性强迫症研究进展[J].中国神经精神疾病杂志,2004,30(6):477-478. 被引量:26
-
2陈强,黄承繁,孙文生.利培酮合并氯丙咪嗪治疗伴强迫症状的分裂症对照研究[J].神经疾病与精神卫生,2004,4(4):296-298. 被引量:9
-
3喻东山.强迫症治疗的新进展[J].中华精神科杂志,2005,38(1):50-52. 被引量:65
-
4刘庆海,李秀玲,靳士立,张玉琦.氯丙嗪与氯丙嗪并氯丙咪嗪治疗精神分裂症强迫症状比较[J].医药导报,1995,14(1):23-24. 被引量:2
-
5肖泽萍.强迫症发病机制的研究现状[J].上海交通大学学报(医学版),2006,26(4):331-334. 被引量:16
-
6高桂林,李翠茹.奥氮平与氯氮平治疗难治性精神分裂症对照研究[J].山东精神医学,2006,19(2):96-97. 被引量:16
-
7匡萃萌,童国荣.泰必利治疗神经症41例疗效观察[J].中国民康医学,2006,18(23):1039-1040. 被引量:1
-
8张一,孟凡强,崔玉华,甘向东,郭伟.修改耶鲁—布朗强迫量表的临床信度和效度研究[J].中国心理卫生杂志,1996,10(5):205-207. 被引量:88
-
9张玉,范习祥.精神分裂症强迫症状研究现状[J].临床心身疾病杂志,2007,13(2):192-192. 被引量:4
-
10[2]Poyurovsky M.Fuchs C,Weizman A.Obsessive compulsive disorder in patients with first episode schizophrenia[J].Am J Psychiatry,1999,156(9):1998-1998
二级引证文献5
-
1潘佳.奥氮平片与氯丙咪嗪共同治疗难治性强迫症患者的临床研究[J].心理月刊,2020,0(2):81-81. 被引量:1
-
2李鑫,夏晓.心理护理对慢性精神分裂症患者强迫症状的效果研究[J].精神医学杂志,2009,22(6):431-433. 被引量:3
-
3蒋燕,王宏刚,王璟.认知行为疗法对慢性精神分裂症患者强迫症状的效果研究[J].四川精神卫生,2010,23(4):227-229. 被引量:1
-
4赵衍山,马文华,周之平,王娟,施潇潇,胡小平.认知行为疗法对慢性精神分裂症患者强迫症状的疗效观察[J].中国民康医学,2016,28(3):9-10. 被引量:3
-
5张卫红.舒必利降低文拉法辛副作用的观察[J].世界最新医学信息文摘,2018,18(27):89-90.
-
1张卫华,周东丰.精神分裂症脑神经影像学及神经病理学的研究进展[J].中华精神科杂志,2003,36(4):249-251. 被引量:13
-
2梁传栋,赵文清,李文玲,王跃红,董慧,郭芳.新生大鼠皮质神经元的体外原代培养及鉴定[J].解放军医学杂志,2008,33(7):906-906. 被引量:5
-
3张炳奎,程宇琪,许秀峰.诱发电位在精神分裂症中的相关应用及研究新进展[J].上海精神医学,2011,23(6):364-367. 被引量:1
-
4宋伟东,潘集阳,刘亚平.失眠障碍的神经影像学研究进展[J].中国神经精神疾病杂志,2015,41(1):62-64. 被引量:5
-
5汪长胜,霍正禄,杨瑞和.脑缺血后白质保护的研究进展[J].国外医学(脑血管疾病分册),2002,10(1):66-68. 被引量:4
-
6李仲铭,徐成丽,朱广瑾.强迫游泳动物模型的研究进展[J].中国行为医学科学,2004,13(5):595-596. 被引量:12
-
7马琪林,钱曾年,顾振纶,杨健身.吡硫醇对缺血和再灌注脑组织血栓烷素B_2等含量变化的影响[J].中华神经科杂志,1994,27(3):152-152.
-
8张明发,金玉洁,沈雅琴.甘草酸保护脑损伤及改善记忆功能的药理作用研究进展[J].药物评价研究,2013,36(1):59-63. 被引量:27
-
9王泽洪,高汝龙.神经生长因子在眼科学中的应用展望[J].自然杂志,1997,19(4):219-223.
-
10曹小定.针刺激活脑内镇痛机能系统而实现针刺镇痛[J].针刺研究,1989,14(1):199-202. 被引量:9